People die on waiting lists because donation alone cannot meet the need

The argument

Proponents of legalisation begin from the shortfall. In every country that relies on unpaid donation, the number of people needing a transplant exceeds the number of organs available, and the gap does not close. Patients wait years, deteriorate while waiting, and some die before an offer comes; others are kept alive by treatments such as dialysis that are expensive, gruelling and far worse than a transplant would be. Proponents argue that this outcome is not a natural limit but a consequence of a policy choice to forbid payment. The argument is that payment would address the shortage because it addresses the reason for it. Donating a kidney to a stranger imposes real costs — surgery, risk, recovery, time away from work — and asks the donor to bear them for nothing. Very few people volunteer, which is unsurprising. Compensation changes the calculation for people who are willing to accept a modest, well-understood risk in exchange for a meaningful sum, and proponents note that we already pay people for other things involving bodily risk and discomfort, including plasma, surrogacy in some jurisdictions and participation in drug trials. Proponents also argue that the current prohibition does not prevent organ selling but exports it. A black market already operates, in which sellers are unscreened, uncompensated for complications and without legal recourse, and buyers travel abroad for surgery of unknown quality. A regulated legal market with medical screening, informed consent, aftercare and a fixed public price would be safer for sellers than the trade that prohibition has produced. Because the donation system leaves people to die of a shortage that payment would reduce, this argument concludes, the sale of human organs should be legalised.

Premises

Counter-arguments

Opponents reply that the shortage can be addressed without a market, through opt-out donation registers, better procurement and investment in alternatives, and that these do not require anyone to sell a kidney. They add that a legal market would likely erode altruistic donation, since giving an organ away becomes a forgone payment and bereaved families may reasonably ask why they should not be paid, so the net gain in supply is far from established.

Rejecting the premises

[Rejecting P1] The shortfall is real, but the premise treats it as a fixed property of unpaid donation when procurement results vary widely between countries operating under the same prohibition. Deficits attributable to consent defaults, hospital referral practice and transplant capacity are counted here as evidence that payment is the missing ingredient. [Rejecting P2] Low volunteer numbers are explained by uncompensated cost alone, but the comparison the premise needs is between systems that reimburse a donor's expenses, lost wages and aftercare and systems that leave them unpaid. If cost were the whole explanation, removing it short of purchase should raise supply. [Rejecting P3] The analogy to plasma, surrogacy and paid trials carries the weight of the argument, yet a kidney is not replenished, so the burden is permanent rather than transient. That a regulated market would displace the black market, rather than operate alongside it and normalise the search for sellers, is asserted rather than shown.